Jetema Co

Jetema Co CROIC

The Cash Return on Invested Capital (CROIC) of Jetema Co (216080.KQ) as of Oct 23, 2026 is -4.15 %. In the previous year, Cash Return on Invested Capital (CROIC) was -2.65 % — a change of 56.55% (lower).

CROIC

-4.15 %

YoY

56.55%

Last updated:

Cash Return on Invested Capital (CROIC) of Jetema Co is 2025 -4.15 % . Cash Return on Invested Capital (CROIC) of Jetema Co was 2024 -2.65 % . It decreases by 56.55% lower compared to the previous year.

The Jetema Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-137.36 KRW
Jan 1, 2019
-43.21 KRW
Jan 1, 2020
-2.64 KRW
Jan 1, 2021
-9.03 KRW
Jan 1, 2022
-30.31 KRW
Jan 1, 2023
-0.17 KRW
Jan 1, 2024
-2.65 KRW
Jan 1, 2025
-4.15 KRW
The Jetema Co CROIC history
YEARCROICYoY
-4.15 %+56.55%
-2.65 %+1,474.93%
-0.17 %-99.44%
-30.31 %+235.52%
-9.03 %+241.78%
-2.64 %-93.88%
-43.21 %-68.54%
-137.36 %+108.18%
-65.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jetema Co Stock analysis

What does Jetema Co do? Jetema Co., Ltd. generates revenue through the manufacturing and distribution of aesthetic products such as dermal fillers, threads, botulinum toxin, and other medical devices. The company develops and sells hyaluronic acid fillers for facial beauty, medical devices for wrinkle, contour, and volume improvement, and laser equipment for treating leukoplakia, psoriasis, and alopecia areata. Additional products include the lifting medical device epiticons, cosmetic mask packs, and pharmaceutical excaine creams. The primary buyers are medical professionals and clinics seeking cosmetic and dermatological solutions. The company's product portfolio targets the aesthetic and medical device market segments, focusing on non-surgical beauty treatments and skin condition therapies. Jetema Co., Ltd. serves customers in the healthcare sector who require advanced medical devices for cosmetic procedures and dermatological care. The business model centers on direct sales of these specialized medical products to healthcare providers and clinics. Jetema Co., Ltd. operates with a workforce of 187 full-time employees based in Wonju, Gangwon-Do, and has been engaged in the development and manufacturing of hyaluronic acid fillers since its inception. The company's offerings are designed to address specific medical and cosmetic needs, with a focus on facial beauty and skin treatments. Revenue is derived from the sale of these medical devices and related products to healthcare professionals and clinics. Jetema Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jetema Co stock

Cash Return on Invested Capital (CROIC) of Jetema Co is -4.15 % in 2025.

Cash Return on Invested Capital (CROIC) of Jetema Co changed from -2.65 % to -4.15 %, representing a 56.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Jetema Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Jetema Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Jetema Co

All Key Metrics — Jetema Co